Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Authors:
Top Cited Papers
Open Access
Abstract
Background: The addition of immune checkpoint inhibitors to standard‐of‐care chemoradiation (CRT) is established as the new standard of care in high‐risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules.Methods: Pembrolizumab was given after or during CRT in a randomized phase 2 design. Patients aged 18 years and older with locally advanced cervical cancer, stages IB–IVA (according to 2009 International Federation of Gynecology and Obstetrics staging) were randomized 1:1 to treatment regimens. CRT was identical for both arms. Pembrolizumab was administered every 3 weeks for three doses; no maintenance was allowed. Safety assessments included the incidence and severity of adverse events (AEs), and feasibility was measured by the completion of treatment in a predefined timeframe. Translational specimens (blood and tissue) were collected.Results: In total, 94 evaluable patients completed treatment. Treatment‐related grade ≥2 toxicity was experienced by 85 of 94 patients (90%); 40 patients (43%) had at least one grade 3 AE, and 22 (23%) had at least one grade 4 AE. There were no grade 5 AEs. Eighty percent of patients completed radiotherapy within 56 days, and 85% completed five or six doses of cisplatin and three doses of pembrolizumab (74 of 94 patients; 79%).Conclusions: The final results of this study support the safety and feasibility of adding pembrolizumab to pelvic CRT, concurrently and sequentially. Progression‐free and overall survival were not affected or different between treatment arms. An analysis of the translational end points is ongoing and will inform future study designs.Keywords
This publication has 13 references indexed in Scilit:
- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county‐level income in the United States, 2000–2019International Journal of Cancer, 2024
- First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826Journal of Clinical Oncology, 2023
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical CancerNew England Journal of Medicine, 2021
- Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancerCancer, 2020
- Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)Clinical Cancer Research, 2020
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2019
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Improved Survival with Bevacizumab in Advanced Cervical CancerNew England Journal of Medicine, 2014
- Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical CarcinomaJAMA, 2007